InvestorsHub Logo
Followers 22
Posts 3225
Boards Moderated 0
Alias Born 01/19/2018

Re: None

Monday, 08/13/2018 6:22:15 AM

Monday, August 13, 2018 6:22:15 AM

Post# of 18649

GTBP CEO, Dr. Raymond Urbanski said:
"This is a tremendous step forward for the OXS-1550 program. Pre-clinical data suggests that the combination of OXS-1550 and this agent is highly potent against certain tumor cell lines. This MTA will allow further studies in animal models to both confirm the effects as well as ascertain which tumor types are the most susceptible to this potent combination."

Don't take my word for it. Dig up your own DD!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GTBP News